drugset
drugset / Trial / NCT00576056

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

NCT00576056 ↗

Phase 2 Terminated 19 enrolled University of Pittsburgh Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.

Timeline

Start
2008-01
Primary completion
2010-03
Completion
2010-04

Outcome

Outcome not reported

Stopped: “Bayer Healthcare is no supplying the study drug”

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral
Background Cisplatin Other / unclassified 125 mg/m2 —

Indications

hepatocellular carcinoma